Thousands of people from Scotland’s most deprived areas will get free weight-loss jabs in a real-world study to gauge if they can save the NHS money.
Duchenne confirmatory trial fails, but Sarepta to ask FDA for full approval anyways
Sarepta Therapeutics’ long-awaited confirmatory study of two of its ‘exon-skipping’ therapies for forms of Duchenne muscular dystrophy failed to meet its primary endpoint, the company


